Immunocore Holdings plc (NASDAQ:IMCR) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC decreased its holdings in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 94.5% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 8,800 shares of the company's stock after selling 151,558 shares during the quarter. SG Americas Securities LLC's holdings in Immunocore were worth $274,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in IMCR. Envestnet Asset Management Inc. boosted its stake in Immunocore by 0.9% in the 2nd quarter. Envestnet Asset Management Inc. now owns 70,571 shares of the company's stock worth $2,392,000 after buying an additional 606 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of Immunocore by 6.5% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 22,622 shares of the company's stock worth $767,000 after acquiring an additional 1,390 shares during the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Immunocore by 2.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 87,614 shares of the company's stock valued at $5,695,000 after purchasing an additional 1,830 shares during the period. DNB Asset Management AS increased its position in Immunocore by 35.0% during the second quarter. DNB Asset Management AS now owns 7,211 shares of the company's stock worth $244,000 after purchasing an additional 1,868 shares during the last quarter. Finally, Orion Portfolio Solutions LLC raised its stake in Immunocore by 33.7% during the first quarter. Orion Portfolio Solutions LLC now owns 23,127 shares of the company's stock worth $1,503,000 after purchasing an additional 5,826 shares during the period. Hedge funds and other institutional investors own 84.50% of the company's stock.

Analyst Ratings Changes

Several analysts have recently issued reports on IMCR shares. Guggenheim cut shares of Immunocore from a "buy" rating to a "neutral" rating in a research note on Monday, October 7th. Morgan Stanley lowered their price target on Immunocore from $80.00 to $74.00 and set an "overweight" rating for the company in a research report on Friday, October 11th. Needham & Company LLC cut their price objective on Immunocore from $81.00 to $78.00 and set a "buy" rating on the stock in a report on Tuesday, September 17th. HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price objective on shares of Immunocore in a research note on Tuesday, September 17th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of Immunocore in a research report on Monday, September 9th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, Immunocore presently has an average rating of "Moderate Buy" and an average price target of $79.82.

Immunocore Stock Down 3.1 %

Shares of NASDAQ IMCR traded down $1.07 during trading on Monday, reaching $33.31. 303,103 shares of the stock were exchanged, compared to its average volume of 546,943. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -27.30 and a beta of 0.72. The business's 50-day moving average price is $33.67 and its 200 day moving average price is $41.68. The company has a quick ratio of 5.15, a current ratio of 5.17 and a debt-to-equity ratio of 1.31. Immunocore Holdings plc has a twelve month low of $29.72 and a twelve month high of $76.98.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.25. The firm had revenue of $75.40 million for the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative net margin of 19.16% and a negative return on equity of 14.68%. The firm's revenue was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.37) EPS. As a group, equities analysts forecast that Immunocore Holdings plc will post -1.67 EPS for the current fiscal year.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.